Personalized DC Vaccine for Postoperative Cancer

Summary

The study is aimed to the test efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for postoperative locally advanced gastric cancer, hepatocellular carcinoma, lung cancer and colorectal cancer, and to explore the biomarkers related to efficacy and adverse event.

Timeline

Start

2019-06-01

Primary completion

2025-12-31

Completion

2026-06-01

Drugs

Indications